Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release (Revised) Jul 10 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a revised press release announcing that it received final approval from the USFDA for Sacubitril and Valsartan Tablets. These tablets are used to treat chronic heart failure in adults and will be manufactured in Ahmedabad, India. The press release highlights that the drug had significant annual sales in the United States.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases